SVB Leerink reiterated coverage on Amryt Pharma with a new price target

3/10/22 4:40:51 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

SVB Leerink reiterated coverage of Amryt Pharma with a rating of Outperform and set a new price target of $10.00 from $9.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AMYT

Date	Price Target	Rating	Analyst
9/6/2022	$19.00	Buy	Canaccord Genuity
3/10/2022	$20.00 → $18.00	Buy	HC Wainwright & Co.
3/10/2022	$9.00 → $10.00	Outperform	SVB Leerink
11/23/2021	$23.00 → $19.00	Outperform	SVB Leerink
10/4/2021	$45.00	Buy	JonesTrading
8/19/2021	$22.00	Outperform	SVB Leerink
8/19/2021	$22.00	Outperform	Cowen
7/27/2021	$29.00	Buy	H.C. Wainwright